Premium
Decreased incidence of acute graft‐versus‐host disease by continuous infusion of cyclosporine with a higher target blood level
Author(s) -
Oshima Kumi,
Kanda Yoshinobu,
Nakasone Hideki,
Arai Shunya,
Nishimoto Nahoko,
Sato Hiroyuki,
Watanabe Takuro,
Hosoya Noriko,
Izutsu Koji,
Asai Takashi,
Hangaishi Akira,
Motokura Toru,
Chiba Shigeru,
Kurokawa Mineo
Publication year - 2008
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21087
Subject(s) - incidence (geometry) , medicine , graft versus host disease , host (biology) , disease , continuous infusion , intensive care medicine , immunology , biology , mathematics , ecology , geometry
Abstract Cyclosporine A (CsA) is the mainstay of pharmacologic prevention of acute graft‐versus‐host disease (GVHD). We previously reported that continuous infusion of CsA with a target blood level between 250 and 400 ng/ml significantly increased the incidence of acute GVHD compared to twice‐daily infusion with a target trough level between 150 and 300 ng/ml. Thus, we raised the target level of CsA continuous infusion to 450–550 ng/ml. We treated 33 patients with the higher target level (CsA500) and compared the efficacy and toxicity with those in the 33 historical control patients (CsA300 group). Other transplantation procedures were not changed. The patients' characteristics were equivalent. The average CsA concentration was adjusted around 500 ng/ml and the actual daily dose was maintained at the initial dose (CsA 3mg/kg/day). Toxicities were equivalently observed among the two groups. The incidence of grades II–IV acute GVHD was significantly lower in the CsA500 group (27 vs. 52%, P = 0.033). The target level of CsA was identified as an independent significant risk factor for grades II–IV acute GVHD ( P = 0.039), adjusted for the presence of HLA mismatch. The incidence of chronic GVHD was also decreased in the CsA500 group (47 vs. 73%, P = 0.016). We conclude that the toxicity of the continuous CsA infusion with a target level of 450–550 ng/ml is acceptable and the efficacy to prevent acute GVHD is significant. A larger comparative study is warranted to confirm these findings. Am. J. Hematol., 2008. © 2007 Wiley‐Liss, Inc.